Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract #5493: Antitumor effects by novel nitrone compound OKN007 in a rat C6 glioma model

Philippe Garteiser, Sabrina Doblas, Debbie Saunders, Yasuko Watanabe, Robert Floyd and Rheal Towner
Philippe Garteiser
Oklahoma Medical Research Foundation, Oklahoma City, OK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabrina Doblas
Oklahoma Medical Research Foundation, Oklahoma City, OK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debbie Saunders
Oklahoma Medical Research Foundation, Oklahoma City, OK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuko Watanabe
Oklahoma Medical Research Foundation, Oklahoma City, OK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Floyd
Oklahoma Medical Research Foundation, Oklahoma City, OK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rheal Towner
Oklahoma Medical Research Foundation, Oklahoma City, OK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

The prognosis of patients who are diagnosed with glioblastoma multiforme is very poor, due to the difficulty of an early and accurate diagnosis and the lack of currently efficient therapeutic compound. In a previous study, we demonstrated the efficiency of phenyl-tert-butylnitrone (PBN) as a potential anti-glioma drug in the pre-treatment of a rat C6 glioma implantation model. However, post-treatment of PBN had little effect for tumor regression compared with pre-treatment. Using the same model, we examined the effect of a novel Nitrone compound, OKN007 that is a structural analog of PBN. The rat glioma model was established by injecting C6 rat glioma cells (106 cells in 10 uL) into the cerebral cortex of male Fischer 344 rats. Fifteen days later, OKN007 was orally administered through drinking water (0.015%, 17.5 mg/kg). The efficacy of OKN007 was assessed using tumor growth patterns and growth rates as determined by magnetic resonance (MR) imaging (T1/T2-weighted imaging) methods. MR results from OKN007 post-treated rats indicated a decrease in tumor volume and delay in tumor growth rate. OKN007 post-treatment was also significantly effective in increasing survival rate. Funds for this study were provided in part by the Oklahoma Medical Research Foundation (OMRF), and a grant (AR071-063) from the Oklahoma Center for the Advancement of Science & Technology (OCAST).

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5493.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #5493: Antitumor effects by novel nitrone compound OKN007 in a rat C6 glioma model
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #5493: Antitumor effects by novel nitrone compound OKN007 in a rat C6 glioma model
Philippe Garteiser, Sabrina Doblas, Debbie Saunders, Yasuko Watanabe, Robert Floyd and Rheal Towner
Cancer Res May 1 2009 (69) (9 Supplement) 5493;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #5493: Antitumor effects by novel nitrone compound OKN007 in a rat C6 glioma model
Philippe Garteiser, Sabrina Doblas, Debbie Saunders, Yasuko Watanabe, Robert Floyd and Rheal Towner
Cancer Res May 1 2009 (69) (9 Supplement) 5493;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Cell Death Pathways and Modulation of DNA Repair -- Poster Presentations - Proffered Abstracts

  • Abstract #5509: Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity
  • Abstract #5499: Overcoming TRAIL resistance by dipyridamole: A new role for an old drug
  • Abstract #5512: Targeting granulin-epithelin precursor in breast cancer
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement